Roche's Phase III ATOMIC Study Drives FDA Priority Review For Tecentriq Plus Chemotherapy As Potential New Standard Of Care In Stage III dMMR/MSI-H Colon Cancer

Roche Reports H1 2026 Revenue Of CHF 30.4B, Up 6% At CER But Down 2% In CHF, As Core EPS Rises 9% At CER To CHF 10.85 From CHF 11.08

FDA Grants Priority Review To Roche's Gazyva/Gazyvaro, Potential First Therapy For Primary Membranous Nephropathy, After Phase III MAJESTY Showed Superior Remission Versus Tacrolimus

Priority Review decision is based on phase III MAJESTY results, where Gazyva/Gazyvaro achieved significantly higher complete remission rates at two years compared to tacrolimus1If approved, Gazyva/Gazyvaro will be the

Roche Introduces Cobas Hepatitis D Virus Test, First Fully Automated Diagnostic Solution To Identify Most Severe Form Of Viral Hepatitis

The new test enables clinicians to reliably diagnose HDV and monitor patients’ treatment response.Hepatitis D affects nearly 12 million of people globally and is considered the most aggressive form of viral hepatitis,

Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight

The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.

AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players

Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.

Merck and Moderna's Phase 3 Win Raises the Stakes for BioNTech and Roche (CORRECTED)

Merck & Moderna's partnership reports first Phase 3 success for personalized cancer vaccine, raising stakes for BioNTech & Genentech's program.